FDA Waiver Of COX-2 Panel Conflicts Draws More Attention On The Hill
This article was originally published in The Tan Sheet
Executive Summary
FDA advisory committee votes in favor of continued availability of COX-2s in the U.S. are "tainted" due to conflicts of interest among panelists, according to a Feb. 25 letter from Senate Finance Committee Chairman Chuck Grassley (R-Iowa)
You may also be interested in...
Draft Conflict Of Interest Policy Affects Status Of Many FDA Cmte. Members
A "significant fraction" of current FDA advisory committee members' eligibility to vote and participate in meetings would be affected by a revised conflict of interest policy, FDA said
Draft Conflict Of Interest Policy Affects Status Of Many FDA Cmte. Members
A "significant fraction" of current FDA advisory committee members' eligibility to vote and participate in meetings would be affected by a revised conflict of interest policy, FDA said
Draft Conflict Of Interest Policy Affects Status Of Many FDA Cmte. Members
A "significant fraction" of current FDA advisory committee members' eligibility to vote and participate in meetings would be affected by a revised conflict of interest policy, FDA said